15 May 2018: The CMA has cleared the completed acquisition by Tiancheng International Investment Limited (part of Creat Group Co., Ltd.) of Biotest AG. The full text of the decision is available below.
23 March 2018: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of merger inquiry
23 March 2018: The CMA announced the launch of its merger inquiry by notice to the parties.
On 31 January 2018 the CMA served an initial enforcement order under section 72(2) of the Enterprise Act 2002 on Tiancheng (Germany)
Pharmaceutical Holdings AG and Bio Products Laboratory Holdings Limited, both subsidiaries of Creat Group Co., Ltd., in relation to the completed acquisition by Tiancheng International Investment Limited (also part of Creat Group Co., Ltd.) of Biotest AG.